2005年9月丹麥哥本哈根舉行的歐洲呼吸學(xué)會(huì)年度大會(huì)上，廣大醫(yī)生呼吁開發(fā)更加有效的輸送設(shè)備以治療哮喘患者。

大多數(shù)哮喘患者不能正確使用他們的吸入器，而且大多數(shù)患者對(duì)他們的治療方案并不依從。倫敦Guy醫(yī)學(xué)院、King醫(yī)學(xué)院、St.Thomas醫(yī)學(xué)院呼吸醫(yī)學(xué)和過敏反應(yīng)系的Brian O'Connor醫(yī)生說：“為了幫助患者，治療方案應(yīng)當(dāng)簡單；應(yīng)當(dāng)說服患者有效地接受治療，給藥方案應(yīng)當(dāng)盡可能的最少。最重要的是，確保患者能夠正確使用吸入器。”

近些年用于治療哮喘的基本治療藥物幾乎沒有什么改變。發(fā)生改變的是用于輸送藥物的設(shè)備。盡管經(jīng)過有效的培訓(xùn)與咨詢，患者仍然面臨困難。使用設(shè)備通常需要良好的手動(dòng)－呼吸協(xié)調(diào)性。出席會(huì)議的醫(yī)生評(píng)估了一種干粉吸入器（DPI），這種新型設(shè)備是專門開發(fā)用于正確而簡單的操作，確保將足量的藥物送入肺部。

這種新型可灌裝設(shè)備叫做Novolizer，使用氣旋作用將顆粒解凝聚，以確保藥物在肺臟的有效分布。該設(shè)備設(shè)計(jì)比目前日常使用的其他設(shè)備更加容易操作，特別適合兒童和老人使用。Novolizer目前在英國獲得批準(zhǔn)應(yīng)用。該設(shè)備是由德國Viatris Pharmaceuticals GmbH (Bad Homburg, Germany)公司研制開發(fā)的。

Asthmatics Need Better Delivery Devices
 
During the annual congress of the European Respiratory Society (ERS), held in Copenhagen (Denmark) in September 2005, clinicians called for more efficient delivery devices for asthma patients.

Most asthma patients cannot use their inhalers correctly and many are noncompliant with their treatment regimens. “To help patients, the treatment plan should be kept simple, the patient should be persuaded of the effectiveness of the treatment, and the dosing regimen should be minimized as much as possible,” said Dr. Brian O’Connor, department of respiratory medicine and allergy, Guy’s, King’s, and St. Thomas’ School of Medicine in London (UK). “Most importantly of all, ensure that the patient can use the inhalers correctly.”

Basic medication used to treat asthma has changed little over the years. What has changed are the numerous devices used to deliver the medications. Despite effective training and counseling, patients are still experiencing problems. Using a device usually requires good hand-breath coordination. Clinicians at the meeting evaluated a new dry powder inhaler (DPI), a novel delivery device that has been specifically developed to be easy to use correctly and ensure deposition of sufficient medication to the lungs.

The new refillable device, called Novolizer, uses a cyclone effect for particle deagglomeration in order to achieve effective lung deposition. It is designed to be easier to operate than many other devices in daily practice, making it easy for children and the elderly to use. The Novolizer is currently approved for use in the United Kingdom for budesonide. The device was developed by Viatris Pharmaceuticals GmbH (Bad Homburg, Germany).